Loading
A phase 2 trial of Decitabine, Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, run by Novartis Pharmaceuticals, active and no longer recruiting.
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. is a phase 2 interventional study registered as NCT05201066 by Novartis Pharmaceuticals, with 33 participants enrolled, started 2023-02-28 and due to reach its primary completion in 2028-02-14. Interventions recorded: decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax and INQOVI (oral decitabine).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Decitabine, Azacitidine, Venetoclax and the tag pipeline.
Shares Decitabine, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/